BioSpace News Archive

According to Vision Research Reports, the global high potency active pharmaceutical ingredients market size was valued at USD 26.75 billion in 2023 and it is expected to surpass around USD 49 billion by 2033 with a CAGR of 6.24% from 2024 to 2033.

The pancreatic cancer market size grew to USD 2.05 billion in 2022 and is estimated to hit approximately USD 7.4 billion by 2032, with a CAGR of 13.7% for the period of 2023 – 2032.

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) is pleased to announce a non-brokered private placement financing (the “Offering”) of up 1,500,000 units of the Company (the “Units”) at a price of $0.40 per Unit, for aggregate gross proceeds of up to $600,000.

Atamyo Therapeutics, a clinical-stage biotechnology company focused on the development of new-generation gene therapies targeting muscular dystrophies and cardiomyopathies, today announced its participation in upcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).

RxSight, Inc. announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its first quarter 2024 financial results on Monday, May 6, 2024, after the market closes.

Exicure, Inc., announced it received a notice of non-compliance from Nasdaq Stock Market LLC on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all periodic financial reports with the U.S.

Artivion, Inc. announced that first quarter 2024 financial results will be released on Monday, May 6, 2024 after the market closes.

ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR) today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.

Kriya Therapeutics, Inc. (“Kriya”), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced six presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, which will be held May 7 to 11, 2024 in Baltimore, MD.